A randomized, placebo-controlled clinical trial of outpatients with COVID-19 found that metformin reduced SARS-CoV-2 viral load 3.6-fold compared to placebo, while ivermectin and fluvoxamine showed no benefit.
ABSTRACT & COMMENTARY
Metformin Reduces SARS-CoV-2 Viral Load in Outpatients with COVID-19
October 1, 2024